---

Novartis (Bangladesh) Limited has officially been renamed Nevian Lifescience PLC following the acquisition of a majority stake by Radiant Pharmaceuticals Limited from Novartis AG Switzerland. The transition was completed after fulfilling all statutory and regulatory requirements, while Bangladesh Chemical Industries Corporation (BCIC) retains its shareholding.

Novartis’ presence in Bangladesh dates back to 1973 with Ciba-Geigy (Bangladesh) Limited, later renamed Novartis (Bangladesh) Limited after the 1996 global merger of Ciba-Geigy and Sandoz AG. Nevian Lifescience PLC now takes forward this 50-year legacy with renewed vision and commitment.

Managing Director Musawath Shams Zahedee said, “Nevian represents continuity of the legacy and commitment for a better tomorrow. While the name is new, our promise remains unchanged — to ensure and expand access to trusted, life-saving medicines for patients in Bangladesh and beyond.”

Nevian will continue manufacturing Novartis’ global brands under license at its EUGMP-certified facility in Tongi, while also expanding exports to the USA, Europe, and other markets, positioning Bangladesh as a global hub for high-quality pharmaceuticals.

The company remains committed to quality, patient safety, and environmental responsibility, including efforts to minimize its carbon footprint.